sofosbuvir + daclatasvir + asunaprevir

This is a combination therapy of three direct-acting antiviral agents (DAAs) used for the treatment of chronic hepatitis C virus (HCV) infection. The combination includes: - Sofosbuvir: A nucleotide-based NS5B inhibitor that prevents HCV RNA synthesis by acting as a "chain terminator" - Daclatasvir: A pangenotypic NS5A inhibitor that inhibits the HCV replication complex - Asunaprevir: A non-structural NS3/4A complex protease inhibitor This all-oral, interferon-free regimen targets multiple aspects of the HCV replication cycle simultaneously, offering high efficacy against various HCV genotypes, particularly genotypes 1 and 3.